Unity Biotechnology (UBX) Competitors $1.94 -0.11 (-5.37%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.03 +0.09 (+4.64%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends UBX vs. STRO, SLN, MCRB, PBYI, CHRS, BMEA, BDTX, CABA, TSVT, and KYTXShould you be buying Unity Biotechnology stock or one of its competitors? The main competitors of Unity Biotechnology include Sutro Biopharma (STRO), Silence Therapeutics (SLN), Seres Therapeutics (MCRB), Puma Biotechnology (PBYI), Coherus BioSciences (CHRS), Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Cabaletta Bio (CABA), 2seventy bio (TSVT), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry. Unity Biotechnology vs. Sutro Biopharma Silence Therapeutics Seres Therapeutics Puma Biotechnology Coherus BioSciences Biomea Fusion Black Diamond Therapeutics Cabaletta Bio 2seventy bio Kyverna Therapeutics Unity Biotechnology (NASDAQ:UBX) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, community ranking, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Which has more volatility & risk, UBX or STRO? Unity Biotechnology has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Do insiders & institutionals believe in UBX or STRO? 29.5% of Unity Biotechnology shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 5.8% of Unity Biotechnology shares are held by company insiders. Comparatively, 5.9% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, UBX or STRO? Unity Biotechnology has higher earnings, but lower revenue than Sutro Biopharma. Unity Biotechnology is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnity Biotechnology$240K136.20-$39.86M-$1.31-1.48Sutro Biopharma$153.73M0.95-$106.79M-$1.61-1.10 Does the media prefer UBX or STRO? In the previous week, Sutro Biopharma had 1 more articles in the media than Unity Biotechnology. MarketBeat recorded 1 mentions for Sutro Biopharma and 0 mentions for Unity Biotechnology. Sutro Biopharma's average media sentiment score of 1.32 beat Unity Biotechnology's score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Unity Biotechnology Neutral Sutro Biopharma Positive Do analysts prefer UBX or STRO? Unity Biotechnology currently has a consensus price target of $7.33, indicating a potential upside of 278.01%. Sutro Biopharma has a consensus price target of $11.13, indicating a potential upside of 528.53%. Given Sutro Biopharma's higher probable upside, analysts plainly believe Sutro Biopharma is more favorable than Unity Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unity Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Sutro Biopharma 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Does the MarketBeat Community believe in UBX or STRO? Unity Biotechnology received 44 more outperform votes than Sutro Biopharma when rated by MarketBeat users. Likewise, 66.67% of users gave Unity Biotechnology an outperform vote while only 66.00% of users gave Sutro Biopharma an outperform vote. CompanyUnderperformOutperformUnity BiotechnologyOutperform Votes17666.67% Underperform Votes8833.33% Sutro BiopharmaOutperform Votes13266.00% Underperform Votes6834.00% Is UBX or STRO more profitable? Unity Biotechnology has a net margin of 0.00% compared to Sutro Biopharma's net margin of -77.01%. Sutro Biopharma's return on equity of -101.89% beat Unity Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Unity BiotechnologyN/A -119.70% -45.86% Sutro Biopharma -77.01%-101.89%-28.69% SummarySutro Biopharma beats Unity Biotechnology on 11 of the 18 factors compared between the two stocks. Get Unity Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UBX vs. The Competition Export to ExcelMetricUnity BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.69M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-1.486.1326.4618.82Price / Sales136.20312.32457.0180.76Price / CashN/A67.8344.0437.47Price / Book1.156.747.634.64Net Income-$39.86M$138.11M$3.18B$245.69M7 Day Performance-11.42%-2.02%-1.82%-2.63%1 Month Performance8.38%-1.54%0.22%-2.37%1 Year Performance10.86%-3.14%17.49%13.65% Unity Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UBXUnity Biotechnology3.8613 of 5 stars$1.94-5.4%$7.33+278.0%+10.9%$34.54M$240,000.000.0060Negative NewsSTROSutro Biopharma4.2576 of 5 stars$1.79+2.9%$11.13+521.5%-61.9%$147.60M$153.73M-1.11240SLNSilence Therapeutics2.4547 of 5 stars$4.84+7.6%$45.00+829.8%-79.9%$144.86M$31.55M-3.08100MCRBSeres Therapeutics3.9958 of 5 stars$0.83-0.9%$5.08+510.5%-23.5%$142.18M$126.32M-3.62330News CoveragePBYIPuma Biotechnology3.7591 of 5 stars$2.86-1.7%$7.00+144.8%-55.5%$140.40M$235.60M5.96200Upcoming EarningsNews CoverageCHRSCoherus BioSciences3.6629 of 5 stars$1.18+1.7%$5.38+355.5%-56.9%$136.75M$257.24M-14.75330BMEABiomea Fusion3.3406 of 5 stars$3.73+3.3%$39.36+955.3%-77.4%$135.17MN/A-0.9350Positive NewsBDTXBlack Diamond Therapeutics3.3899 of 5 stars$2.37+1.3%$15.50+554.0%-53.7%$134.10MN/A-1.7890Short Interest ↓Positive NewsCABACabaletta Bio2.2546 of 5 stars$2.71+0.4%$22.71+738.2%-90.7%$132.47MN/A-1.2650Analyst ForecastTSVT2seventy bio2.1813 of 5 stars$2.54-0.4%$7.20+183.5%-53.2%$131.03M$45.62M-1.37440Analyst ForecastNews CoverageKYTXKyverna Therapeutics1.1679 of 5 stars$3.03-0.3%$25.71+748.7%-89.9%$130.81M$7.03M0.0096 Related Companies and Tools Related Companies Sutro Biopharma Competitors Silence Therapeutics Competitors Seres Therapeutics Competitors Puma Biotechnology Competitors Coherus BioSciences Competitors Biomea Fusion Competitors Black Diamond Therapeutics Competitors Cabaletta Bio Competitors 2seventy bio Competitors Kyverna Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UBX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unity Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unity Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
